Category: St. Jude Medical
St. Jude won a regulatory green-light in Japan for the only commercially available pacemaker and lead system safe during a full-body, high-resolution MRI.
St. Jude Medical won approval in Japan for the 1st commercially available pacemaker and lead system deemed safe during a full-body, high-resolution MRI.
Japanese regulators cleared St. Jude Medical's (NYSE:STJ) MRI-safe pacemaker and lead devices, the 1st such devices commercially available there, according to the medical device company.
St. Jude Medical says that patients implanted - and fitted - with its Amplatzer patent foramen ovale closure device showed benefits not seen in the larger trial.
Medical device giant St. Jude Medical (NYSE:STJ) is taking another swing at clinical trial data for its Amplatzer patent foramen ovale closure device, reporting that a narrower view of the patient population shows that Amplatzer does help reduce strokes.
European healthcare regulators approve St. Jude Medical’s next-generation Quadra Assura MP cardiac synchronization defibrillator with multi-point pacing capability.
St. Jude Medical (NYSE:STJ) today announced CE Mark approval in the European Union for its latest in multi-point cardiac pacing, the Quadra Assura MP cardiac synchronization defibrillator.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
St. Jude Medical's Durata implantable cardiac defibrillator leads should be "relatively immune" to the problems that led to a recall for the medical device company's Riata ICD leads, according to a cardiologist who helped bring the Riata problems to light.
St. Jude Medical (NYSE:STJ) pulled its Riata implantable cardiac defibrillator leads in 2010 after mounting evidence suggested that the Riata leads were prone to abrading through their insulation. The move cast a pall over over St. Jude's newer ICD lead offerings, the Riata ST Optim and Durata leads.
St. Jude Medical won FDA approval for its portfolio of next-generation high voltage defibrillators featuring new safety features that provide extra electrical insulation and prevent shorts from obstructing life-saving therapy.
St. Jude Medical (NYSE:STJ) today won FDA approval for the next generation in its portfolio of high-voltage devices, which include safety features that overcome some common problems with implantable defibrillators.
St. Jude Medical makes a $40 million equity investment into Spinal Modulation in exchange for international distribution rights and an exclusive option to buy the neurostimulation devices maker for up to $300 million.
St. Jude Medical (NYSE:STJ) last week branded neurostimulation devices maker Spinal Modulation as its territory with a $40 million equity investment that gives St. Jude international distribution rights and an exclusive option to acquire the company down the road.